Bone preservation and the menopause

British Journal of Hospital Medicine

Volumn 57, Issue 5, 1997, Pages 212-214

  Fraser, William D ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D;

BONE DENSITY; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HUMAN; MIDDLE AGED; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; WOMEN'S HEALTH;

BONE DENSITY; CALCIUM; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D; WOMEN'S HEALTH;

EID: 0031553763     PISSN: 00071064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Albright F, Smith PH, Richardson AM (1941) Postmenopausal osteoporosis: its clinical features. JAMA 116:2464-74
2. Black D, Cummings S, Karpf DB et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-41
3. Black D, Cummings S, Melton LJ (1992) Appendicular bone mineral and a woman's life-time risk of hip fracture. J Bone Miner Res 7: 639-46
4. Chapuy M, Arlot M, Duboeuf F et al (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Eng! J Med 327: 1637-42
5. Chapuy M, Arlot M, Delmas P, Meunier P (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 308: 1081-2
6. Christensen MS, Hagen C, Christiansen C, Transbol I (1982) Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 63: 759-63
7. Christiansen C, Christensen MS, Transbol I (1981) Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet i: 459-61
8. Christiansen C, Riis BJ (1990) Five years therapy with continuous combined oestrogenJ progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 97: 1087-92
9. Cooper C, Melton LJ (1992) Vertebral fractures: how large is the silent epidemic? Br Med J 304: 793-4
10. Cummings ST, Kelsey JL, Nevitt MC, O'Dowd KJ (1985) Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7: 178-208
11. Grey AB, Cundy TF, Reid IR (1994) Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol40:67-7
12. Heath DA, Bullivant BG, Webber D, Pack S, Balena R (1996) Effects of cyclical etidronate therapy in the prevention of bone loss in early postmenopausal women. J Bone Min Res 11 (Suppl 1):M644
13. Hoskmg DJ, McClung MR, Ravn P et al (1996) Alendronate in the prevention of osteoporosis: EPIC study two-year results.J Bone Miner Res 11 (Suppl I): 153
14. Kanis JA, Melton LJ III, Christiansen C, Johnston CG, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137-41
15. Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. Br Med J 307: 1248-50
16. Lindsay R, Aitken JM, Anderson JB (1976) Longterm prevention of postmenopausal osteoporosis by oestrogen. Lancet i: 1038-40
17. Lindsay R, Hart DM, Clark HD (1984) The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63: 759-63
18. Lindsay R, Hart DM, Abdalla H, Al-Azzawi F (1987) Inter-relationship of bone loss and its prevention, and fracture expression. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Osteopress, Copenhagen: 508-12
19. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorenensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N EnglJ Med 322: 1265-71
20. Watts NB, Harris ST, Genant HK et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Ensl J Med 323: 73-9